Literature DB >> 19200823

Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy.

Paolo Durando1, Pietro Crovari, Filippo Ansaldi, Laura Sticchi, Camilla Sticchi, Valter Turello, Lorenzo Marensi, Raffaella Giacchino, Anna Timitilli, Roberto Carloni, Chiara Azzari, Giancarlo Icardi.   

Abstract

Liguria was the first Italian Administrative Region, since 2003, to actively recommend free-of-charge immunisation, of all infants, with heptavalent Pneumococcal Conjugate Vaccine (PCV-7), within a research pilot-project. Vaccination coverage among infants rapidly increased from 42.8% in 2003 to 83.3% in 2004, progressively reaching levels of 93.4% in 2007. Two scientific projects have been carried out, aimed: (i) to assess the immunogenicity of PCV-7 and of a hexavalent vaccine Diphtheria-Tetanus-Trivalent Acellular Pertussis-Hepatitis B-Inactivated Polio Virus-Haemophilus influenzae type B (DTaP-HBV-IPV-Hib) when co-administered to healthy infants at 3, 5 and 11-12 months of age (routine schedule), and (ii) to evaluate the effect of the immunisation campaign in preventing pneumococcal-associated hospitalisations. Results in 151 infants showed the high immunogenicity of the vaccines, seroprotection rates, measured 1 month after the third dose, ranging between 97.3% (serotype 6 B) and 100% (serotypes 4 and 9 V) for PCV-7 and between 99.3% and 100% against common antigens of hexavalent vaccine. Monitoring nearly 70,000 children, aged 0-24 months, during the period 2000-2007, and comparing hospitalisation rates occurred in subjects belonging to birth cohorts before and after the introduction of widespread immunisation, a significant decline for all-cause and pneumococcal pneumonia and for acute otitis media was observed, with preventive fractions of 15.2%, 70.5% and 36.4%, respectively.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19200823     DOI: 10.1016/j.vaccine.2009.01.052

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  25 in total

1.  Significant decline in pneumonia admission rate after the introduction of routine 2+1 dose schedule heptavalent pneumococcal conjugate vaccine (PCV7) in children under 5 years of age in Kielce, Poland.

Authors:  M Patrzałek; P Albrecht; M Sobczynski
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-01       Impact factor: 3.267

2.  Impact of implementing French antibiotic guidelines for acute respiratory-tract infections in a paediatric emergency department, 2005-2009.

Authors:  F Angoulvant; D Skurnik; H Bellanger; H Abdoul; X Bellettre; L Morin; M Aptecar; G Galli-Gibertini; O Bourdon; C Doit; A Faye; J-C Mercier; R Cohen; C Alberti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-16       Impact factor: 3.267

3.  Indirect population impact of universal PCV7 vaccination of children in a 2 + 1 schedule on the incidence of pneumonia morbidity in Kielce, Poland.

Authors:  M Patrzalek; P Gorynski; P Albrecht
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-16       Impact factor: 3.267

4.  Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children ≤5 years after its implementation into the national immunization program of Turkey.

Authors:  Erdem Gönüllü; Ahmet Soysal; Ismail Yıldız; Gökhan Aydemir; Turan Tunç; Metin Karaböcüoğlu
Journal:  Hum Vaccin Immunother       Date:  2020-03-02       Impact factor: 3.452

5.  Carriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children: rationale and perspectives for PCV13 implementation.

Authors:  Filippo Ansaldi; Daniela de Florentiis; Paola Canepa; Antonella Ceravolo; Emanuela Rappazzo; Rocco Iudici; Mariano Martini; Gerardo Botti; Andrea Orsi; Giancarlo Icardi; Paolo Durando
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

6.  Serotypes of Streptococcus pneumoniae isolates from children with invasive pneumococcal disease in Turkey: baseline evaluation of the introduction of the pneumococcal conjugate vaccine nationwide.

Authors:  Mehmet Ceyhan; Nezahat Gurler; Akgun Yaman; Candan Ozturk; Lutfiye Oksuz; Sengul Ozkan; Melike Keser; Nuran Salman; Emre Alhan; Duygu Esel; Meral Gultekin; Yildiz Camcioglu; Mustafa Gul; Yelda Sorguc; Sohret Aydemir; Murat Gunaydin; Yusuf Yakupogullari; Ahmet Kizirgil
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

7.  A retrospective analysis of hospital discharge records for S. pneumoniae diseases in the elderly population of Florence, Italy, 2010-2012.

Authors:  Angela Bechini; Cristina Taddei; Alessandro Barchielli; Miriam Levi; Emilia Tiscione; Maria Grazia Santini; Fabrizio Niccolini; Maria Teresa Mechi; Donatella Panatto; Daniela Amicizia; Chiara Azzari; Paolo Bonanni; Sara Boccalini
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

8.  Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants.

Authors:  Shabir A Madhi; Alane Izu; Avye Violari; Mark F Cotton; Ravindre Panchia; Els Dobbels; Poonam Sewraj; Nadia van Niekerk; Patrick Jean-Philippe; Peter V Adrian
Journal:  Vaccine       Date:  2012-12-08       Impact factor: 3.641

9.  Long-term immune protection against HBV: associated factors and determinants.

Authors:  Marianna Mastrodomenico; Mario Muselli; Luca Provvidenti; Maria Scatigna; Serena Bianchi; Leila Fabiani
Journal:  Hum Vaccin Immunother       Date:  2021-01-31       Impact factor: 3.452

10.  Routine infant immunization with the 7- and 13-valent pneumococcal conjugate vaccines: current perspective on reduced-dosage regimens.

Authors:  Teresa Jackowska; Justyna Pluta
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.